CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 46 enrolled
Drug / intervention
Walnut Diet +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02210767
NCT02210767N/ACompleted
CompareCT.gov

Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors

Penn State University·interventional·Posted Aug 7, 2014·Updated Aug 21, 2023

In Brief

A clinical study evaluating Walnut Diet, Walnut Control Diet, and 1 other intervention for Cardiovascular Disease. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This study will evaluate the effects of walnut-derived ALA and bioactives on multiple CVD risk factors, including central blood pressure, arterial stiffness indices, inflammatory markers, urinary isoprostanes, vascular adhesion markers, and changes in lipids and lipoproteins. Gut microbiome changes due to walnut consumption will also be assessed using the 16S rRNA gene.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesUnited States
CollaboratorsCalifornia Walnut Commission

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 7, 2014
Enrollment StartAug 1, 2014
Primary CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.9 years ago

Interventions

Walnut Dietother

2 oz. walnuts/day (2-3% of total calories from ALA)

Walnut Control Dietother

2-3% ALA but no walnuts provided

Low ALA Dietother

ALA replaced by oleic acid